531 related articles for article (PubMed ID: 30989461)
21. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
Wu J; Xiao S; Yuan M; Li Q; Xiao G; Wu W; Ouyang Y; Huang L; Yao C
Mol Med Rep; 2019 Jan; 19(1):75-84. PubMed ID: 30431088
[TBL] [Abstract][Full Text] [Related]
23. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
25. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
[TBL] [Abstract][Full Text] [Related]
26. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
27. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
28. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
29. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
31. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
32. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
[TBL] [Abstract][Full Text] [Related]
33. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
[TBL] [Abstract][Full Text] [Related]
35. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
36. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
37. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
39. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
Kharat SS; Ding X; Swaminathan D; Suresh A; Singh M; Sengodan SK; Burkett S; Marks H; Pamala C; He Y; Fox SD; Buehler EC; Muegge K; Martin SE; Sharan SK
Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817374
[TBL] [Abstract][Full Text] [Related]
40. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
